CALL 347-637-2631 TO JOIN BY PHONE AND ASK QUESTIONS
Dr. Noa Biran of the John Theurer Cancer Center at Hackensack University joins HealthTree Podcast for Multiple Myeloma to discuss a completely new approach targeting CD38, which is found on most myeloma cells. The drug called modafakusp alpha (formerly known as TAK-573) uses a new method of targeting CD38 by combining a monoclonal antibody with interferon. Early trial results are showing that this treatment option could also work for patients who relapsed after anti-CD38 monoclonal antibodies like daratumumab and isatuximab.
Inteferon is a human hormone that has been previously used in myeloma care because it can both kill the myeloma cells directly and engage the immune system to fight the myeloma, but it had many intolerable side effects. In this new form combined with modafakusp alpha, the side effects are significantly reduced. This new drug is now in clinical trials being tested with common myeloma therapies like dexamethasone, daratumumab, proteasome inhibitors and immunomodulators. Learn about this new treatment option in this informative show.
Having new treatment options, especially after patients have relapsed after the three most common drug classes (proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies) is a blessing for relapsed or refractory patients.
We appreciate your donations to support the HealthTree Foundation Podcast.
Welcome, Announcements & Introduction
A discussion with Dr. Biran about modafakusp alpha: how it works, how it is being tested in clinical trials and how it can still be effective for patients who have relapsed following daratumumab or isatuximab.
Audience is able to call in to the radio show. Call 347-637-2631 and press 1 on your keypad to ask Dr. Biran questions about what was discussed during our interview today.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Noa Biran, MD, is an associate professor in the Myeloma Division of the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. She is actively involved in clinical research with a focus on high-risk disease and the role of minimal residual disease in multiple myeloma. Dr. Biran has presented a range of clinical work at international and national conferences such as the American Society of Hematology and the Society of Hematologic Oncology. She is widely published in hematology and oncology journals such as the American Journal of Hematology, Current Hematologic Malignancy Reports, and The Hemophilia Report. She has also co-authored the chapter “Oncologic Emergencies” in Essentials of Hospital Medicine: A Practical Guide for Clinicians. Prior to joining the John Theurer Cancer Center faculty, Dr. Biran served as Chief Fellow of Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, New York. She also practiced in their internal medicine internship and residency and participated in numerous lecture series and training sessions for medical students, residents, and nurse practitioners. She received her medical degree from The George Washington University in Washington, D.C.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113